Axsome Therapeutics Reports Strong Q4 & Full Year 2025 Results with Key Pipeline Milestones
AXSM has more than doubled off its 52-week low of $86.99.
Summary
Axsome Therapeutics announced strong Q4 and full year 2025 financial results with significant revenue growth, reduced net loss, and positive cash flow guidance, alongside key pipeline advancements including Priority Review for AXS-05 and an upcoming NDA for AXS-12.
Key Events · Earnings and Guidance · AXSM
-
Strong Commercial Performance
Total net product revenue for full year 2025 reached $638.5 million, representing 66% year-over-year growth. AUVELITY sales grew 74% year-over-year to $507.1 million, and SUNOSI revenue increased 32% to $124.8 million for the full year.
-
Improved Financials and Cash Runway
The company reported a reduced net loss of $183.2 million for the full year 2025, down from $287.2 million in 2024. Axsome believes its current cash of $322.9 million (as of Dec 31, 2025) is sufficient to fund anticipated operations into cash flow positivity.
-
AXS-05 Granted Priority Review
The sNDA for AXS-05 for the treatment of Alzheimer's disease agitation was granted Priority Review by the FDA, with a PDUFA target action date of April 30, 2026. A pivotal Phase 2/3 trial for smoking cessation is planned for Q2 2026.
-
AXS-12 NDA Submission Imminent
Axsome is on track to submit the New Drug Application (NDA) for AXS-12 in narcolepsy this quarter, following positive pre-NDA meeting minutes from the FDA.
Analysis · AXSM · Life Sciences
Axsome Therapeutics delivered robust financial results for Q4 and full year 2025, driven by significant revenue growth from its commercial products, AUVELITY and SUNOSI. The company also reported a substantial reduction in net loss and provided positive guidance on its cash runway, projecting funding into cash flow positivity. Beyond financials, the filing highlights critical advancements in its pipeline, including Priority Review for AXS-05 in Alzheimer's disease agitation with an April 2026 PDUFA date, and the imminent NDA submission for AXS-12 in narcolepsy. These combined factors indicate strong operational execution and a promising outlook for future growth and regulatory approvals, reinforcing investor confidence as the stock trades near its 52-week high.
At the time of this filing, AXSM was trading at $184.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $86.99 to $191.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.